HALO Latest Press Releases

-- November 6, 2026 --

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 PRNewswire 10:05 AM

U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer PRNewswire 9:57 AM

-- November 5, 2026 --

HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE PRNewswire 4:05 PM

-- October 22, 2026 --

Halozyme to Report Third Quarter 2026 Financial and Operating Results PRNewswire 8:30 AM

-- October 7, 2026 --

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets PRNewswire 8:30 AM

-- October 6, 2026 --

Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE Technology PRNewswire 4:05 PM

-- September 30, 2026 --

Halozyme Announces Appointment of Jim Daly to its Board of Directors PRNewswire 4:05 PM

-- September 17, 2026 --

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 PRNewswire 11:21 PM

-- September 16, 2026 --

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 PRNewswire 4:31 PM

-- September 2, 2026 --

Halozyme to Participate at Upcoming Investor Conferences PRNewswire 8:31 AM

-- August 18, 2026 --

Halozyme Appoints Dannielle Appelhans to its Board of Directors PRNewswire 4:01 PM

-- August 6, 2026 --

HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE PRNewswire 4:01 PM

-- July 23, 2026 --

Halozyme to Report Second Quarter 2026 Financial and Operating Results PRNewswire 8:30 AM

-- July 20, 2026 --

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology PRNewswire 8:00 AM

-- June 30, 2026 --

Halozyme Appoints David Ramsay as President Drug Delivery PRNewswire 4:02 PM

-- June 15, 2026 --

Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 PRNewswire 6:01 AM

Market Data Delayed 15 Minutes